www.brainwork.md – Accredited eLearning for neurologists.

An online neurology network at your fingertips!

Join and become a member of our community for access to:

Up-to-the-minute reporting from international conferences, Accredited CME courses by world-renowned experts, Coverage of the latest scientific and clinical information,
… and much more!

JOIN

Latest news

25th October 2021

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-04_antibody.png 6641 3734 Samuel Krebs Samuel Krebs https://secure.gravatar.com/avatar/fc8fd5388a4b0dab003e549cd46f68f2?s=96&d=mm&r=g 25th October 2021 25th October 2021

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus, natalizumab is associated with a risk of progressive multifocal leukoencephalopathy…

To stay or to switch? Assessing long-term treatment outcomes and impact of treatment on patients’ quality of life

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-03_stay_or_switch.png 6641 3734 Samuel Krebs Samuel Krebs https://secure.gravatar.com/avatar/fc8fd5388a4b0dab003e549cd46f68f2?s=96&d=mm&r=g 22nd October 2021 22nd October 2021

The main concerns of patients, regarding their treatment, include disease control and safety, but they also want to make sure that their day-to-day life remains…

Samuel Krebs
0

20th October 2021

Getting the complete clinical picture: A closer look at smouldering MS

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-02_inflammation-.png 6641 3734 Samuel Krebs Samuel Krebs https://secure.gravatar.com/avatar/fc8fd5388a4b0dab003e549cd46f68f2?s=96&d=mm&r=g 20th October 2021 21st October 2021

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS,…

Samuel Krebs
0

20th October 2021

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-06-20211019_illustration-01_Wellness.png 5692 3201 Samuel Krebs Samuel Krebs https://secure.gravatar.com/avatar/fc8fd5388a4b0dab003e549cd46f68f2?s=96&d=mm&r=g 20th October 2021 21st October 2021

A growing body of evidence suggests that integrative medicine (IM) modalities can enhance the comprehensive care of patients with multiple sclerosis (MS). Thirty to eighty…

Samuel Krebs
0

8th October 2021

Speaking to Prof. Barbara Tettenborn – “You have to love what you do, otherwise you are not good”

https://www.brainwork.md/content/uploads/2021/10/Brainwork-Prof-Barbara-Tettenborn-Interview-1.jpg 1500 1001 Anna Stelling, PhD Anna Stelling, PhD https://secure.gravatar.com/avatar/03d32c6dd44674dd6ad1a82129cbc197?s=96&d=mm&r=g 8th October 2021 8th October 2021

Prof. Barbara Tettenborn is the chief of the Department of Neurology at the Cantonal Hospital St. Gallen, Switzerland since 1999. In addition to her position…

Anna Stelling, PhD
0

BrainworkFollow

Brainwork @brainwork_md·

8 Oct

What does Barbara Tettenborn do in her rare free time? And what does she think about taking on more political roles recently? Read about her career, her private and professional ambitions & more in our new spotlight interview on Brainwork https://tinyurl.com/y5sa66ss
#WomeninNeurology

Brainwork @brainwork_md·

20 Sep

New guidelines for the use of #MRI in patients with #MultipleSclerosis sclerosis have recently been published. Check out our news article to find out more about the most important updates and recommendations! https://www.brainwork.md/new-guidelines-for-the-use-of-mri-in-patients-with-multiple-sclerosis/

Brainwork @brainwork_md·

27 Aug

Not all experiences with #stroke are equal. Women can experience greater burden and risks due to stroke than men. At Stroke Summer School 2021, Professor Christine Kremer gave a talk on sex differences in stroke. Read more here: https://www.brainwork.md/the-female-stroke-sex-differences-affect-stroke-presentation-and-management/

Brainwork @brainwork_md·

26 Aug

During the “Stroke Summer School 2021", Stefan Engelter presented the latest news on #dopamine in #stroke rehabilitation and shared unpublished data from the Swiss #ESTREL trial. Read the full article: https://bit.ly/3jlNtqJ

Brainwork @brainwork_md·

20 Aug

During this year’s “Stroke Summer School 2021”, Gian Marco De Marchis from the Stroke Unit of the University Hospital Basel, provided an overview of the most important recent findings regarding #lipids and #stroke. Read the full article: https://www.brainwork.md/lipids-and-stroke-an-update/

Courses

Myotonic Disorders

In this course, accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and the Swiss Medical Association (FMH), a healthcare professional will provide the participant with an overview of myotonic disorders.

select course

Management of Epilepsy during Pregnancy

In this course, accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and the Swiss Medical Association (FMH), healthcare professionals will provide the participant with a clear understanding of the important considerations for women with epilepsy when planning a pregnancy.

select course

Prognosis and Treatment Strategy in RRMS

In this course, accredited by the European Accreditation Council for Continuing Medical Education (EACCME) and the Swiss Medical Association (FMH), healthcare professionals will provide the participant with an overview of the applications of machine learning approaches to stroke diagnosis and monitoring.

select course

view more courses

Events

27th October 2017

Welcome to Brainwork

https://www.brainwork.md/content/uploads/2017/10/MPR426-Brainwork-illustrations-articles-V00-02-20171027_neurons.png 899 506 Prof. Dr. Krassen Nedeltchev Prof. Dr. Krassen Nedeltchev https://secure.gravatar.com/avatar/aaadc696c1b66fe476051e7e4012d01a?s=96&d=mm&r=g 27th October 2017 27th October 2017

Prof. Dr. Krassen Nedeltchev
3
7

18th January 2018

80-year track record of neurosurgical success

https://www.brainwork.md/content/uploads/2018/01/Brainwork-80yearstrackrecord.jpg 1600 1605 Jared Ou-Young, MSc Jared Ou-Young, MSc https://secure.gravatar.com/avatar/1352535dba6be2a178b009ce2c0b64a3?s=96&d=mm&r=g 18th January 2018 13th July 2018

Jared Ou-Young, MSc
0
1

25th April 2018

A conversation with Dr Jens Kuhle

https://www.brainwork.md/content/themes/anemos/images/empty/thumbnail.jpg 150 150 Lutz Achtnichts, MD Lutz Achtnichts, MD https://secure.gravatar.com/avatar/c84206ad1869ec28d770e94fa456ef6d?s=96&d=mm&r=g 25th April 2018 13th July 2018

Lutz Achtnichts, MD
0
2

6th March 2018

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide

https://www.brainwork.md/content/uploads/2018/03/Brainwork-MS.jpg 1600 1067 Julien Ferrari, PharmD, PhD Julien Ferrari, PharmD, PhD https://secure.gravatar.com/avatar/3b67ea7b895dced9b9ed9795a9851ab4?s=96&d=mm&r=g 6th March 2018 13th July 2018

Julien Ferrari, PharmD, PhD
0
2

View more events

An online neurology network at your fingertips!

Latest news

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

To stay or to switch? Assessing long-term treatment outcomes and impact of treatment on patients’ quality of life

Getting the complete clinical picture: A closer look at smouldering MS

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

Speaking to Prof. Barbara Tettenborn – “You have to love what you do, otherwise you are not good”

Courses

Myotonic Disorders

Management of Epilepsy during Pregnancy

Prognosis and Treatment Strategy in RRMS

Events

Welcome to Brainwork

​80-year track record of neurosurgical success

A conversation with Dr Jens Kuhle

ZINBRYTA® (daclizumab) voluntarily withdrawn from markets worldwide

80-year track record of neurosurgical success

ZINBRYTA^® (daclizumab) voluntarily withdrawn from markets worldwide